UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13A-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of April 2018
COMMISSION FILE Number. 000-29338
CARDIOME PHARMA CORP.
(Translation of registrant’s name into English)
1441 Creekside Drive, 6th floor
Vancouver, British Columbia, V6J 4S7, CANADA
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F
Form 20-F ☒ | Form 40-F ☐ |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED AS PART OF THIS REPORT
Exhibit | Description | |
99.1 | News Release dated April 26, 2018 - Cardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CARDIOME PHARMA CORP. | ||
(Registrant) | ||
Date: April 26, 2018 | By: | /s/ Justin Renz |
Name: Justin Renz | ||
Title: Chief Financial Officer |
Exhibit 99.1
Cardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference
NASDAQ:CRME, TSX:COM
VANCOUVER, April 26, 2018 /CNW/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Mr. David Dean, Chief Business Development Officer of Cardiome, will present at the Bloom Burton & Co. Healthcare Investor Conference. The presentation will take place at the Sheraton Centre Hotel Toronto on Wednesday, May 2, 2018 at 11:30 a.m. EST in Toronto, Canada.
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients. With a commercial presence and distribution network covering over 60 countries worldwide, Cardiome develops, acquires and commercializes brands for the in-hospital, acute care market segment. The Company's portfolio of approved and marketed brands includes: Xydalba™ (dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera®/Mabelio® (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital acquired pneumonia (CAP, HAP); Brinavess® (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat® (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome, and Esmocard® and Esmocard Lyo® (esmolol hydrochloride), a short-acting beta-blocker used to control rapid heart rate in a number of cardiovascular indications. Cardiome's pipeline of product candidates includes Trevyent®, a drug device combination that is designed to deliver treprostinil, the world's leading treatment for pulmonary arterial hypertension.
Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.
Cardiome® and the Cardiome Logo are the proprietary
trademarks of Cardiome Pharma Corp.
Aggrastat® and Brinavess® are trademarks owned by Cardiome and its affiliates worldwide.
XydalbaTM is a trademark of Durata Therapeutics Holding C.V., and used under license.
Zevtera® and Mabelio® are trademarks owned by Basilea Pharmaceutica International Ltd., and used
under license.
Esmocard® and Esmocard Lyo® are trademarks owned by Orpha-Devel Handels und Vertriebs GmbH, and used
under license.
Trevyent® is a trademark of SteadyMed and used under license.
All other trademarks are the property of their respective owners.
View original content:http://www.prnewswire.com/news-releases/cardiome-to-present-at-the-bloom-burton--co-healthcare-investor-conference-300637695.html
SOURCE Cardiome Pharma Corp.
View original content: http://www.newswire.ca/en/releases/archive/April2018/26/c7834.html
%CIK: 0001036141
For further information: Justin Renz, CFO, Cardiome Pharma Corp., 604.677.6905 ext. 128, 800.330.9928, jrenz@cardiome.com; Argot Partners, Michelle Carroll, 212.600.1902, michelle@argotpartners.com
CO: Cardiome Pharma Corp.
CNW 16:33e 26-APR-18
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
F87Y
MG$69RV=!8L=,0(.GUSD"]5=_<.S7596%79.FBJ:_O/Z+=RM")8#KR*\0-]?V
M[K$7&N),@&UKS"L)^%8^-?+"0;@[:/7L6_Z=ZR=V+AM:8O6NX-W[.XY\%[
MK1->QZ37OVJ@;22PK[>Z)3\WI,PF=SCSW*,;-H?[IT=V34O:[D*M82U*A KL
M^V+_P3Q 8.HRZ'%[G3L=$UZO.BY\*4!AXEO!O4$8)+D'E>J$&JH9C $,8_6[
MW59D)(2>*"*JB":BGY@F3A%7"-HG#SAQP_I"J5_T;_ ?\A-3_A_[X2_]P"^;
MQ@*ZLJ541KZQ6"$D_UB8DW$"=EFLZ!6= #'F.XS(32"E**S*(MLI_<.3)+
M#V\TV3QK)P_]M4FI4?&%\>V1S8.-SX3;JEH:RQ*V+*5*J5'GAAS?OO;1R_4;
MB MM*[<^/_,(N["CCV98%< ]2QMW@N#E5Z_%FS>]<[1;5. JEJ-5JELG3MYQ
M2H0S]NB?((:;, UFP$(BK9K!*6XF5RZ"I['5.KD/<@S &(ZQ,?B_T2J=![V8
MD?MB.+EM_I[4"J5>J%N4B H5G( >O@:^ <1N
MAV26.-J$M)HB:8$?N;-0_#=0WI=-YL;C[?7+*@M):*!9HQG2%E=_*'RR^/V5
M)S8YC18%%1LD2R1EX@61-BMU^;=]O[CTM>)UI'A]\DM^PN%].=W#QY^Q^ZPDXKL
M7?D*#8 * %;7N<%(H/*#EX2&LL[NU2L0Y^& ^K2WWKK:E]_Z2L_97 !0$4H2
M?[82@%0IH+'P8/^Y5Y&V.5B8-W2(BK-:2",.EXUW%67Z_:")17KQLU.$AK
M5)=ZW)U/9.?I_L]S]<
V;TWZ#^OWRB[*'+\9;/WN3.W1S[+?_<",/#VQ& ;S3C8
M"ZMHKB(\\/.OCTY>OW'896G$>JDLW8,?0SMR;SW$%_-$S]+]*V9GHF=NZ=LK
M-FDEU 0
;1=X?$O0WF;WZ:-E2%DQ6GE/3B
ML?;<^;N/#]D@T%2>= UB1O 8'Q:8W%!!8@;!2&J;?8#?83&*B:
MX)7?:1,K$^A$LK%976XHRK8:*4H 'C1%J2+B2$/=\17+X"\1E@)=ZA7-H DN47C[EVR;-^RI+F'QC^5
M:./.TG-8BV?D^O\KM;R%N:/L_S(WRI+Y#(R7_41CD<932= P;O'5Y)>2/ID9YV?!&8\")"VF*B#Q8$9>E$8-DU^RZUJUD".S%7,C[
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MN.D6 *?%2!0V,%TV7:6T%9D"G9J'3KR(TP&8L_G%PCSF#OA\W+ST%WPLA])'VGQMW07]1C5P^-ZQW1:6:?3ZKQ:']?8
M:T=V>Z/"7&5N,?";!.)
M1&>"2R12Y-\BTHA(G)CTS_MQGW_(/^EGB7_,C_VGJR<80HB;-)%59(A\3H0F
MHA#<1PX3+#($9
Y!7^8N*/B3N)SQ*<83TRK ^M[UW/&EO;B:T\U4ZT
MAI1^>OX+Q6:QIO2.@:JJP0&6/Q>Y&KD5N1OA(B.P=QG%D9+T6]JEUGZ#TP6)
M<*\58LP)WRT?ONE#/@J*4YZFQIO0(JE1EV=GT>S+,E?5@_2/KU/7J$)/5OZ @9.9L\.W)V
MZ2P^4PED,L7 _*PA"+(Q,,7O!_N;X/N:!RV.%//%M>+M(F$4[Q51H0B*37!#
M;>3,+$H
M?L(KN2.>8"+8$QP/
1-L>OMV%=BU 3W'5;2Y:NEJ2U5KB
MP],HY->OGU"M6C#-\/)06#2;S3WNA*LI-/K)/[*AN$<:<+H]-AO;X@W8_9\8
M/OX:Z@K 3$^_\6>2G3))[P.6K?3W _$,'8$K3__M[\IJ\2G#X_I5?#3B?-J/
MT-THW@ PO*6L*O\R/*[U;O@Q7]>56R60)7B,E>%)/@V[V05(ZQ9@A,]#!YF!
M^Y@T?(M)JROL#'3C^$F
WKAW[_I,>\U6WY!T29$=@
M<*^_HV?SD-EM>NGL;/-")N0?F1B CSTJ/O@F?AM;41,:D@W(7?O1'+_,4WP%
M#]QTL^>M%=PIVWG0.RIP$4[F)CGF.H
CD&< #A+,&:_:*&A'TD0],EV,]QNM?*Q]JV-NZ6J]5B
M)0%>Z?,%4L^3ONYKW3P)&&"A" :8F1J$DFH,H^-0PM[ #RB?%Z.@C#YBV5V6
MRIZRM^PK^\N!
C&U(H9:1G323$Y"5X:&7'$DX;])+=K7P$ FN)U>%S+K=HE$RC];N!:
M-R0M9CCTW(LFNIY *'<@DJ!5C1D:F9 M<<"P)/V?49^)6E#',]LSDX/^=M&R
MP\JR$[39>6D1'R41M"D+L+IZ$4$]?_RRP@E$MV)*DBR*K#3"(B (\N6I_\R?
M>>WH%1;E&(+!*38^QPID/#1_>1Q:7#CPV:GP0!!'20=PE!!->,A;*3W:@+?N
M//FI],H+4Q_LGG-V[[XZO"[ZV]%MJ3G]G[/XW)R- Z?!S:<(47!+$%<:KD<;0%=?WIEJRAL
ML9LQ#,<./%V#7\-ZS(OMP :4U@.NL< EYP^KYIU7JZY5W2$_96]930?P ]+=
M'83O$$W4'[*Q#>TGV_'D!=X"%K3P&+GP.6+)3? 0:^,?3_Z?[7(+;N(ZX_B>
MO7A7UUWMKB1+MF3K9ETL:V7)EBW;N[K$-WS!PF!L(:\53#$)!(P!=PCATC@4
MZG:2,)FD#X46FC33"4D:IC04FC2AS4 ?FA#2Z37MT#3CI--)/.FD3*=]0/2<
ME!%L<2Z1H%:,9()I$Q(@V)@2]QW](WKAVZ"Q-2^RK'*"Q-#G9$1W>[C,4>C
M%7]A\H0W':=QZ.C-O+O;O2_]T)6]!HJ@ ^_AWSM\9,NW%Y-GOO[R&Y6/*@\9
M&+.#5);&8P='\6YX[=^?3.QAVB-Y((9O-[B2%E?'*J6J.FW:75D\OG
MB)7%MZ]